Skip to main content
Clinical Trials/NCT02935374
NCT02935374
Completed
Phase 4

Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children: A Randomized Controlled Trial

University of Oulu1 site in 1 country73 target enrollmentNovember 2016

Overview

Phase
Phase 4
Intervention
Macrolide
Conditions
Acute Otitis Media
Sponsor
University of Oulu
Enrollment
73
Locations
1
Primary Endpoint
Change in the relative abundance of Firmicutes in stool samples
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This is a randomized, controlled trial studying the effects of various antimicrobial treatments on the intestinal microbiome of small children. The participating children with acute otitis media are treated wither with amoxicillin, amoxicillin-clavulanate or without antibiotics. The children with allergy to amoxicillin receive a course of macrolide and they will be monitored as a separate group. The main outcomes of this trial are the changes in the intestinal microbiome after the treatment.

Detailed Description

Antimicrobial treatment of acute otitis media has been proven efficacious in children. It has been suggested that antimicrobial treatment makes a lot of harm to intestinal microbiome and may thus have effects on the child's health and wellbeing. However, data on these changes and their magnitude is scanty. This is a randomized, controlled trial studying the effects of various antimicrobial treatments on the intestinal microbiome of small children. The participating children with acute otitis media are treated wither with amoxicillin, amoxicillin-clavulanate or without antibiotics. The children with allergy to amoxicillin receive a course of macrolide and they will be monitored as a separate group. The main outcomes of this trial are the changes in the intestinal microbiome after the treatment.

Registry
clinicaltrials.gov
Start Date
November 2016
End Date
March 2020
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • acute symptoms of respiratory infection AND
  • signs of inflammation on the tympanic membrane in otoscopy AND
  • middle ear effusion found in pneumatic otoscopy

Exclusion Criteria

  • Suspected or proven complication of acute otitis media (for example acute mastoiditis or perforated tympanic membrane)
  • Severe acute otitis media: severe pain and fever \> 39 degrees C
  • Bilateral acute otitis media in a child younger than 2 years
  • Primary or secondary immunodeficiency or Downs syndrome
  • Impaired general condition or suspected severe bacterial infection
  • Allergy to both amoxicillin and macrolide
  • Acute otorrhea through tympanostomy tube
  • Antimicrobial treatment ongoing or during previous 7 days

Arms & Interventions

Macrolide

The children with acute otitis media with known allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored as a separate group, outside randomization.

Intervention: Macrolide

Amoxicillin

The children with acute otitis media will be treated with amoxicillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.

Intervention: Amoxicillin

Amoxicillin-Potassium Clavulanate

The children with acute otitis media will be treated with amoxicillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.

Intervention: Amoxicillin-Potassium Clavulanate

Outcomes

Primary Outcomes

Change in the relative abundance of Firmicutes in stool samples

Time Frame: Change from baseline to 10 days

Change in the relative abundance of Firmicutes in stool samples obtained at baseline and at 10 days after the diagnosis of acute otitis media.

Secondary Outcomes

  • Change in the relative abundance of Lactobacilli in stool samples(Change from baseline to 10 days)
  • Change in the relative abundance of Actinobacteria in stool samples(Change from baseline to 10 days)
  • Change in the relative abundance of Faecalibacterium prausnitzii in stool samples(Change from baseline to 10 days)
  • Change in the diversity of fecal microbiota measured with the number of operational taxonomic units (OTUs)(Change from baseline to 10 days)
  • Principal coordinate analysis (PCA) of fecal samples(10 days)
  • Change in the relative abundance of Bacteroidetes in stool samples(Change from baseline to 10 days)
  • Change in the relative abundance of Proteobacteria in stool samples(Change from baseline to 10 days)
  • Change in the relative abundance of Verrucomicrobia in stool samples(Change from baseline to 10 days)
  • Change in the relative abundance of Bifidobacteria in stool samples(Change from baseline to 10 days)
  • Change in the diversity of fecal microbiota measured with Shannon index(Change from baseline to 10 days)
  • Change in the diversity of fecal microbiota measured with Chao index(Change from baseline to 10 days)
  • Presence of antimicrobial genes measured with the means of metagenomics(10 days)
  • Proportion of Clostridium difficile -positive fecal samples(10 days)
  • Proportion of fecal samples with Extended Spectrum Beta-Lactamase -positive strains(10 days)

Study Sites (1)

Loading locations...

Similar Trials